(Total Views: 568)
Posted On: 08/01/2020 10:15:14 AM
Post# of 153995
really,
I agree releasing the safety data by itself appears to have been a mistake in hindsight. However, I believe the whole CytoDyn team felt the data was going to be better received. It showed SAEs much better than Remdesivir. Putting myself in their shoes, I am not sure I would have thought differently.
What is the correct approach for data release? Wait till it's all together or piecemeal it out. In the former case, the stockholders are holding their breath so long they may pass out. In the latter, we have the ongoing circus of partial news, shorts, etc. Its like living a reality TV show everyday, but as we learn these bits of information the risk seems to go down. I think Dr. L said the data just keeps confirming the value of the drug. Of course the former is what the rest of the BP world does ...
I agree releasing the safety data by itself appears to have been a mistake in hindsight. However, I believe the whole CytoDyn team felt the data was going to be better received. It showed SAEs much better than Remdesivir. Putting myself in their shoes, I am not sure I would have thought differently.
What is the correct approach for data release? Wait till it's all together or piecemeal it out. In the former case, the stockholders are holding their breath so long they may pass out. In the latter, we have the ongoing circus of partial news, shorts, etc. Its like living a reality TV show everyday, but as we learn these bits of information the risk seems to go down. I think Dr. L said the data just keeps confirming the value of the drug. Of course the former is what the rest of the BP world does ...
(1)
(0)
